Revance Therapeutics (RVNC) Misses Q4 EPS by 11c

Revance Therapeutics (NASDAQ: RVNC) reported Q4 EPS of ($0.95), $0.11 worse than the analyst estimate of ($0.84). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $70 thousand.

2017 Financial Outlook

Revance reiterates its financial guidance provided in January 2017. Revance expects cash burn for 2017 to be in the range of $102 to $112 million. Revance expects 2017 GAAP operating expense to be in the range of $108 to $119 million, which when excluding depreciation of $1 to $2 million and estimated stock-based compensation of $13 to $15 million, results in projected 2017 non-GAAP operating expense of $94 to $102 million. With three clinical programs underway, Revance anticipates 2017 GAAP research and development expense to be in the range of $75 to $83 million, which when excluding depreciation of $1 to $2 million and estimated stock-based compensation of $5 to $6 million, results in projected 2017 non-GAAP research and development expense of $69 to $75 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Sunstone Hotel Investors to sell Hyatt Regency San Francisco for $279M
• Prosperity Bancshares (PB) Reiterated at Overweight by Cantor Fitzgerald as Estimates Revised